Stifel Nicolaus Forecasts Strong Price Appreciation for TransMedics Group (NASDAQ:TMDX) Stock

TransMedics Group (NASDAQ:TMDX) had its price target lifted by equities research analysts at Stifel Nicolaus from $75.00 to $80.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The brokerage presently has a “hold” rating on the stock. Stifel Nicolaus’ price objective points to a potential upside of 9.26% from the company’s previous close.

Several other equities analysts have also issued reports on the company. Canaccord Genuity Group decreased their target price on TransMedics Group from $152.00 to $124.00 and set a “buy” rating for the company in a research report on Wednesday, May 6th. Oppenheimer lowered TransMedics Group from an “outperform” rating to a “market perform” rating in a research report on Wednesday, May 6th. Wall Street Zen cut TransMedics Group from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Weiss Ratings reiterated a “hold (c)” rating on shares of TransMedics Group in a report on Tuesday, June 9th. Finally, UBS Group reiterated a “hold” rating on shares of TransMedics Group in a report on Tuesday, May 26th. Six investment analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company’s stock. According to MarketBeat.com, TransMedics Group currently has an average rating of “Hold” and an average target price of $134.50.

TransMedics Group Price Performance

TransMedics Group stock opened at $73.22 on Thursday. The firm has a market capitalization of $2.53 billion, a P/E ratio of 16.64 and a beta of 1.91. TransMedics Group has a 1 year low of $60.10 and a 1 year high of $156.00. The business has a 50-day moving average of $84.57 and a 200-day moving average of $113.51. The company has a current ratio of 6.74, a quick ratio of 6.19 and a debt-to-equity ratio of 1.70.

TransMedics Group (NASDAQ:TMDX) last posted its earnings results on Tuesday, May 5th. The company reported $0.30 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.62 by ($0.32). The company had revenue of $173.93 million for the quarter, compared to analyst estimates of $174.44 million. TransMedics Group had a return on equity of 22.38% and a net margin of 27.04%.TransMedics Group’s quarterly revenue was up 21.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.70 earnings per share. On average, equities analysts anticipate that TransMedics Group will post 1.98 EPS for the current year.

Insider Buying and Selling at TransMedics Group

In other news, Director Thomas J. Gunderson sold 9,624 shares of TransMedics Group stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $75.06, for a total transaction of $722,377.44. Following the transaction, the director owned 16,642 shares in the company, valued at $1,249,148.52. The trade was a 36.64% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 6.90% of the stock is owned by company insiders.

Hedge Funds Weigh In On TransMedics Group

Institutional investors have recently modified their holdings of the business. Harvest Fund Management Co. Ltd bought a new position in shares of TransMedics Group during the 3rd quarter valued at about $29,000. Allworth Financial LP lifted its holdings in shares of TransMedics Group by 74.3% during the 3rd quarter. Allworth Financial LP now owns 265 shares of the company’s stock valued at $30,000 after purchasing an additional 113 shares in the last quarter. Optiver Holding B.V. boosted its position in TransMedics Group by 248.1% during the 3rd quarter. Optiver Holding B.V. now owns 268 shares of the company’s stock worth $30,000 after acquiring an additional 191 shares during the last quarter. Parallel Advisors LLC boosted its position in TransMedics Group by 42.1% during the 4th quarter. Parallel Advisors LLC now owns 280 shares of the company’s stock worth $34,000 after acquiring an additional 83 shares during the last quarter. Finally, Ascentis Independent Advisors acquired a new position in TransMedics Group during the 1st quarter worth approximately $30,000. Institutional investors own 99.67% of the company’s stock.

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.